FREQUENCY OF V600E MUTATION IN BRAF GENE AMONG PATIENTS WITH METASTATIC MELANOMA
DOI:
https://doi.org/10.63356/asb.2024.003Keywords:
metastatic melanoma, molecular analysis, BRAF V600E mutation, gender and age categories of patientsAbstract
This paper presents an overview of the frequency of V600E mutation in BRAF gene among patients with metastatic melanoma during the period from 2014 to 2018 at the University Clinical Centre in Banja Luka. Detection of mutations in BRAF gene was performed on 393 FFPET (formalin-fixed, paraffin-embedded tissue) skin tissue samples using the BRAF test through PCR (polymerase chain reaction) a standardized method for clinical analyses. Histopathological and molecular analyses of all samples were conducted at the Laboratory for Immunohistochemical and Molecular Diagnostics, Institute of Clinical Pathology, University Clinical Centre in Banja Luka. Study results clearly indicate that more than half of patients with metastatic melanoma carry V600E mutation in BRAF gene. Analysis confirms that high- quality quantity of DNA was successfully isolated from a large number of FFPET skin samples for mutation testing. Over the five-year study period, a statistically significant higher number of men than women were diagnosed with metastatic melanoma. Regarding the presence of mutations in the BRAF gene in relation to gender, frequency of BRAF+ and BRAF- samples was equal among men, while women had more BRAF+ samples compared to BRAF-. The average age of all patients with metastatic melanoma from the University Clinical Centre in Banja Luka was relatively low, only 58.62 years. The age group with the highest frequency of metastatic melanoma patients was between 55 and 65 years. BRAF V600E oncogenic mutations are among the most commonly identified molecular alterations in genomes of patients with metastatic melanoma and serve as the basis for selecting the best therapy. Detection of BRAF V600E mutations is an extremely applicable and widely used method that provides excellent results in clinical practice for selecting the optimal combination of cytostatic and treating metastatic melanoma today.
References
Anderson, S., Bloom, J. K. & Vallera, U. (2012). Multisite Anallytic Performance Studies of a Real-Time Polymerase Chain Reaction Assay for the Detection of BRAFV600 Mutations in Formalin-Fixed, Paraffin-Embedded Tissue Specimens of Malignant Melanoma. Archives of Pathology and Laboratory Medicine, 136(11), 1385-1391. https://doi.org/10.5858/arpa.2011-0505-OA
Champan, P. B., Hauschild, A. & Robert, C. (2011). Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. New England Journal of Medicine, 364(26), 2507–2516. DOI: 10.1056/NEJMoa1103782
Chat-Uthai, N., Vejvisithsakul, P. & Udommethaporn, S. (2018). Development of ultra-short PCR assay to reveal BRAF V600 mutation status in cancer tissues. Archives of Pathology and Laboratory Medicine,13(6):e0198795. https://doi.org/10.1371/journal.pone.0198795
Clarke, C. A., McKinley, M. & Hurley, S. (2017). Continued Increase in Melanoma Incidence across all Socioeconomic Status Groups in California, 1998–2012. Journal of investigative dermatology, 137(11), 2282–2290. http://dx.doi.org/10.1016/j.jid.2017.06.024
Cooper, M., Geoffrey, E. & Hausman, R. (2010). The cell: A molecular approach, peto izdanje. Zagreb: Medicinska naklada.
Curry, J. L., Torres-Cabala, C. A. & Tetzlaf, M. T. (2012). Molecular Platforms Utilized to Detect BRAF V600E Mutation in Melanoma. Cutaneous Medicine and Surgery, 31(4), 267-273. http://dx.doi.org/10.1016/j.sder.2012.07.007
Duncan, L. M. (2009). The classification of cutaneous melanoma. Hematology/oncology clinics of North America, 23(9), 501–513. https://doi.org/10.1016/j.hoc.2009.03.013
Jurkowska, M., Gos, A., Ptaszyński, K., Michej, W., Tysarowski, A., Zub, R., Siedlecki, J. A. & Rutkowski, P. (2015). Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes. International Journal of Clinical and Experimental Pathology, 8(7), 8487–8493. https://pubmed.ncbi.nlm.nih.gov/26339422/
Kim, S. Y., Kim, S. N. & Hahn, H. J. (2015). Metaanalysis of BRAF mutations and clinicopathologic characteristics in melanoma. Journal of American Academy of Dermatology, 72(6), 1036–1046. https://doi.org/10.1016/j.jaad.2015.02.1113
Kong, Y. B., Carlino, S. M. & Menzies, M. A. (2016). Biology and treatment of BRAF mutantmetastatic melanoma. Melanoma Management, 3(1), 33–45. https://doi.org/10.2217/mmt.15.38
Kraemer, K. H., Lee, M. M. & Andrews, A. D. (1994). The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. Archives of dermatology, 130(8), 1018– 1021. https://pubmed.ncbi.nlm.nih.gov/8053698/
Longshore, J., Banawan, S. & Amidon, H. (2015). Comparison of Molecular Testing Methods for Detecting BRAF V600 Mutations in Melanoma Specimens with Challenging Attributes. Journal of Molecular Biomarkers & Diagnosis, 6(1), 215. https://doi.org/10.4172/2155-9929.1000215
Mahual, B. A., Edge, S. B. & Greene, F. L. (2017). AJCC Cancer Staging Manual, 8th Ed. Springer.
Malicherove, B., Burjanivova, T. & Grendar, M. (2018). Droplet digital PCR for detection BRAF V 600E mutation in formalin-fixed, paraffin-embedded melanoma tissues: acomparison with Cobas®, Sanger sequencing, allele-specific PCR. American Journal of Translational Research, 10(11), 3773-3781. https://pubmed.ncbi.nlm.nih.gov/30662627/
Mourah, S., Denis, M. G. & Narducci, F. E. (2015). Detection of BRAF V600 Mutations in Melanoma: Evaluation of Concordance between the Cobas 4800 BRAF V600 Mutation Test and the Methods Used in French National Cancer Institute (INCa). Journal of Clinical Pathology, 10(3):e0120232. https://doi.org/10.1371/journal.pone.0120232
O'Brien, O., Lyons, T. & Murphy, S. (2017). BRAF V 600 mutation detection in melanoma: a comparison of two laboratory testing methods. Journal of Clinical Pathology, 70(11), 935–940. https://doi.org.10.1136/jclinpath-2017-204367
Pearlstein, M. V., Zedek., C. D. & Ollila D. W. (2014). Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma. Journal of Cutaneous Pathology, 41(2), 724- 732. https://doi.org/10.1111/cup.12364
Rigel, D. S. (2010). Epidemiology of melanoma. Cutaneous medicine and surgery, 29(4), 204–209. DOI: 10.1016/j.sder.2010.10.005
Roh, M. R., Eliades, P. & Gupta, S. (2017). Cutaneous melanoma in women. International Journal of Women׳s Dermatology, 3(1),11–15. https://doi.org/10.1016/j.ijwd.2017.02.003
Qu, K., Pan, Q. & Zhang, X. (2013). Detection of BRAF V600 Mutations in Metastatic Melanoma Comparison of Cobas 4800 and Sanger Sequenc Assays. Journal of Molecular Diagnostics, 15(6), 790-795. https://doi.org/10.1016/j.jmoldx.2013.07.003
Santiago, W. A., Gagnon, R. & Mazumdar, J. (2015). Correlation of BRAF mutation status in circulating free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clinical Cancer Research, 22(3), 567–574. https://doi.org/10.1158/1078-0432.CCR-15-0321
Swetter, S. M., Galler, C. A. & Kirkowood, M. J. (2004). Melanoma in the Older Person.
Oncology Journal, 18(9), 1187-1196. https://pubmed.ncbi.nlm.nih.gov/15471201/
Tas, F. & Erturk, K. (2017). Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival. Molecular and Clinical Onkology, 7(1), 1083–1088. https://doi.org/10.3892/mco.2017.1439
Tsao, H. & Niendorf, K. (2004). Genetic testing in hereditary melanoma. Journal of the American Academy of Dermatology, 51(5), 803–808. https://doi.org/10.1016/j.jaad.2004.04.045
Wu, Y. P., Kohlmann, W. & Curtin, K. (2017). Melanoma risk assessment based on relatives' age at diagnosis. Cancer causes & control, 29(2), 193–199. https://doi.org/10.1007/s10552-017-0994-8
Zocco, D., Bernardi, S. & Novelli, M. (2020). Isolation of extracellular vesicles improves the detection of mutant DNA from plasma od metastatic melanoma patients. Natura Scientific Reports 10(15745). https://www.nature.com/articles/s41598-020-72834-6
